Cambridge Investment Research Advisors Inc. grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.1% in the third quarter, HoldingsChannel reports. The firm owned 193,571 shares of the biopharmaceutical company’s stock after purchasing an additional 4,028 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Gilead Sciences were worth $15,683,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Keel Point LLC lifted its holdings in shares of Gilead Sciences by 0.4% during the 2nd quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock worth $221,000 after acquiring an additional 12 shares during the last quarter. Paradigm Financial Advisors LLC lifted its holdings in shares of Gilead Sciences by 0.3% during the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after acquiring an additional 26 shares during the last quarter. Princeton Portfolio Strategies Group LLC lifted its holdings in shares of Gilead Sciences by 0.4% during the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $691,000 after acquiring an additional 41 shares during the last quarter. Arrow Financial Corp lifted its holdings in shares of Gilead Sciences by 0.3% during the 2nd quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock worth $1,258,000 after acquiring an additional 45 shares during the last quarter. Finally, Auxier Asset Management lifted its holdings in shares of Gilead Sciences by 1.4% during the 2nd quarter. Auxier Asset Management now owns 6,773 shares of the biopharmaceutical company’s stock worth $479,000 after acquiring an additional 96 shares during the last quarter. Hedge funds and other institutional investors own 75.95% of the company’s stock.

A number of analysts have recently issued reports on the stock. BidaskClub downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Credit Suisse Group set a $80.00 price objective on shares of Gilead Sciences and gave the stock a “hold” rating in a report on Wednesday, January 3rd. BMO Capital Markets reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Wednesday, January 3rd. Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, December 21st. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $85.03.

Gilead Sciences, Inc. (GILD) opened at $79.02 on Tuesday. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The stock has a market cap of $103,190.00, a PE ratio of 8.99, a P/E/G ratio of -1.68 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter in the previous year, the company earned $2.75 earnings per share. Gilead Sciences’s quarterly revenue was down 13.2% on a year-over-year basis. research analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.63%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.66%.

In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now owns 77,363 shares in the company, valued at $5,788,299.66. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the completion of the sale, the insider now owns 3,070,099 shares in the company, valued at approximately $230,656,537.87. The disclosure for this sale can be found here. Insiders have sold 461,666 shares of company stock worth $34,072,567 in the last quarter. 1.30% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This news story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/01/16/gilead-sciences-inc-gild-stake-lifted-by-cambridge-investment-research-advisors-inc.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related stocks with our FREE daily email newsletter.